Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations

被引:20
作者
Farkas, Andras [1 ,2 ]
Daroczi, Gergely [3 ]
Villasurda, Phillip [4 ]
Dolton, Michael [5 ]
Nakagaki, Midori [6 ]
Roberts, Jason A. [6 ,7 ,8 ,9 ]
机构
[1] Mt Sinai West Hosp, Dept Pharm, New York, NY 10019 USA
[2] Optimum Dosing Strategies, Bloomingdale, NJ 07403 USA
[3] EasyStats Ltd, London, England
[4] Vassar Bros Med Ctr, Dept Pharm, Poughkeepsie, NY USA
[5] Univ Southern Calif, Sch Biomed Engn, Los Angeles, CA USA
[6] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
[7] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[8] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[9] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia
关键词
INVASIVE FUNGAL-INFECTIONS; CRITICALLY-ILL PATIENTS; INTRAVENOUS VORICONAZOLE; ATTRIBUTABLE MORTALITY; TRANSPLANT RECIPIENTS; DISEASES SOCIETY; ADULT PATIENTS; 2016; UPDATE; SAFETY; EFFICACY;
D O I
10.1128/AAC.00970-16
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Bayesian methods for voriconazole therapeutic drug monitoring (TDM) have been reported previously, but there are only sparse reports comparing the accuracy and precision of predictions of published models. Furthermore, the comparative accuracy of linear, mixed linear and nonlinear, or entirely nonlinear models may be of high clinical relevance. In this study, models were coded into individually designed optimum dosing strategies (ID-ODS) with voriconazole concentration data analyzed using inverse Bayesian modeling. The data used were from two independent data sets, patients with proven or suspected invasive fungal infections (n = 57) and hematopoietic stem cell transplant recipients (n = 10). Observed voriconazole concentrations were predicted whereby for each concentration value, the data available to that point were used to predict that value. The mean prediction error (ME) and mean squared prediction error (MSE) and their 95% confidence intervals (95% CI) were calculated to measure absolute bias and precision, while Delta ME and Delta MSE and their 95% CI were used to measure relative bias and precision, respectively. A total of 519 voriconazole concentrations were analyzed using three models. MEs (95% CI) were 0.09 (-0.02, 0.22), 0.23 (0.04, 0.42), and 0.35 (0.16 to 0.54) while the MSEs (95% CI) were 2.1 (1.03, 3.17), 4.98 (0.90, 9.06), and 4.97 (-0.54 to 10.48) for the linear, mixed, and nonlinear models, respectively. In conclusion, while simulations with the linear model were found to be slightly more accurate and similarly precise, the small difference in accuracy is likely negligible from the clinical point of view, making all three approaches appropriate for use in a voriconazole TDM program.
引用
收藏
页码:6806 / 6812
页数:7
相关论文
共 38 条
  • [21] Factors associated with overall and attributable mortality in invasive aspergillosis
    Nivoix, Yasmine
    Velten, Michel
    Letscher-Bru, Valerie
    Moghaddam, Alireza
    Natarajan-Ame, Shanti
    Fohrer, Cecile
    Lioure, Bruno
    Bilger, Karin
    Lutun, Philippe
    Marcellin, Luc
    Launoy, Anne
    Freys, Guy
    Bergerat, Jean-Pierre
    Herbrecht, Raoul
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (09) : 1176 - 1184
  • [22] Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies
    Nomura, K.
    Fujimoto, Y.
    Kanbayashi, Y.
    Ikawa, K.
    Taniwaki, M.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (11) : 1141 - 1143
  • [23] Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
    Pappas, Peter G.
    Kauffman, Carol A.
    Andes, David R.
    Clancy, Cornelius J.
    Marr, Kieren A.
    Ostrosky-Zeichner, Luis
    Reboli, Annette C.
    Schuster, Mindy G.
    Vazquez, Jose A.
    Walsh, Thomas J.
    Zaoutis, Theoklis E.
    Sobel, Jack D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2016, 62 (04) : E1 - E50
  • [24] The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
    Park, Wan Beom
    Kim, Nak-Hyun
    Kim, Kye-Hyung
    Lee, Seung Hwan
    Nam, Won-Seok
    Yoon, Seo Hyun
    Song, Kyoung-Ho
    Choe, Pyoeng Gyun
    Kim, Nam Joong
    Jang, In-Jin
    Oh, Myoung-don
    Yu, Kyung-Sang
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 55 (08) : 1080 - 1087
  • [25] Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
    Pascual, Andres
    Calandra, Thierry
    Bolay, Saskia
    Buclin, Thierry
    Bille, Jacques
    Marchetti, Oscar
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 46 (02) : 201 - 211
  • [26] Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections
    Pascual, Andres
    Csajka, Chantal
    Buclin, Thierry
    Bolay, Saskia
    Bille, Jacques
    Calandra, Thierry
    Marchetti, Oscar
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 55 (03) : 381 - 390
  • [27] Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
    Patterson, Thomas F.
    Thompson, George R., III
    Denning, David W.
    Fishman, Jay A.
    Hadley, Susan
    Herbrecht, Raoul
    Kontoyiannis, Dimitrios P.
    Marr, Kieren A.
    Morrison, Vicki A.
    Nguyen, M. Hong
    Segal, Brahm H.
    Steinbach, William J.
    Stevens, David A.
    Walsh, Thomas J.
    Wingard, John R.
    Young, Jo-Anne H.
    Bennett, John E.
    [J]. CLINICAL INFECTIOUS DISEASES, 2016, 63 (04) : E1 - E60
  • [28] Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens
    Purkins, L
    Wood, N
    Ghahramani, P
    Greenhalgh, K
    Allen, MJ
    Kleinermans, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) : 2546 - 2553
  • [29] Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
    Roberts, Jason A.
    Abdul-Aziz, Mohd H.
    Lipman, Jeffrey
    Mouton, Johan W.
    Vinks, Alexander A.
    Felton, Timothy W.
    Hope, William W.
    Farkas, Andras
    Neely, Michael N.
    Schentag, Jerome J.
    Drusano, George
    Frey, Otto R.
    Theuretzbacher, Ursula
    Kuti, Joseph L.
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (06) : 498 - 509
  • [30] The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human
    Roffey, SJ
    Cole, S
    Comby, P
    Gibson, D
    Jezequel, SG
    Nedderman, ANR
    Smith, DA
    Walker, DK
    Wood, N
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (06) : 731 - 741